Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Sector Gamma AS

Sector Gamma AS lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 39.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 32,092 shares of the biopharmaceutical company's stock after selling 20,876 shares during the period. Alnylam Pharmaceuticals comprises approximately 1.5% of Sector Gamma AS's portfolio, making the stock its 23rd largest position. Sector Gamma AS's holdings in Alnylam Pharmaceuticals were worth $6,143,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Truist Financial Corp acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $474,000. Semanteon Capital Management LP acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $308,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $416,000. State of New Jersey Common Pension Fund D increased its holdings in Alnylam Pharmaceuticals by 2.3% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 73,259 shares of the biopharmaceutical company's stock valued at $14,023,000 after purchasing an additional 1,674 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its holdings in Alnylam Pharmaceuticals by 5.8% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,575 shares of the biopharmaceutical company's stock valued at $684,000 after purchasing an additional 195 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ALNY shares. BMO Capital Markets restated an "outperform" rating and issued a $234.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. Needham & Company LLC restated a "buy" rating and issued a $200.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. Cantor Fitzgerald restated a "neutral" rating and issued a $165.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. HC Wainwright restated a "buy" rating and issued a $395.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 5th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a "neutral" rating in a research note on Thursday, February 1st. Eight research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $215.88.

Alnylam Pharmaceuticals Stock Down 0.3 %

ALNY traded down $0.40 on Friday, reaching $143.31. The company had a trading volume of 479,139 shares, compared to its average volume of 467,891. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $218.88. The stock has a market capitalization of $18.05 billion, a PE ratio of -40.26 and a beta of 0.39. The stock has a 50-day moving average price of $150.21 and a 200-day moving average price of $165.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating analysts' consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to analysts' expectations of $439.38 million. During the same period last year, the firm earned ($1.68) earnings per share. Alnylam Pharmaceuticals's revenue was up 31.2% on a year-over-year basis. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -4.46 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.